Does the possibility accorded to Penn Central, under the landmark preservation regulation, of realizing some value at some time by transferring the Terminal development rights to other buildings, under a procedure that is conceded to be defective, severely limited, procedurally complex and speculative, and that requires ultimate discretionary
approval by governmental authorities, meet the constitutional requirements of just compensation as applied to landmarks?
These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted
by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory
approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to
governmental payers; the FDA or regulatory
authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization
by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made
by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.
Educational software makers may get rebuffed
by authorities like Lyon, whose endorsements, companies believed, could lead to
governmental stamps of
approval, and thus explosive sales.
Local regulations generally require additional disclosures
by the parties to a real estate transaction or their agents or brokers, or the receipt of reports or certifications, often from the local
governmental authority, prior to the closing or settlement of a real estate transaction as well as prescribed review and
approval periods for documentation and broker conditions for review and
approval.